CTI signs deal with Peak Industries
Computerized Thermal Imaging (CTI) has chosen Peak Industries of Frederick, CO, to manufacture the patient examination bed for its breast cancer detection system. The system uses thermal imaging technology to help users determine whether abnormalities
Computerized Thermal Imaging (CTI) has chosen Peak Industries of Frederick, CO, to manufacture the patient examination bed for its breast cancer detection system. The system uses thermal imaging technology to help users determine whether abnormalities found in breast tissue are malignant. The unit is in clinical trials to explore its efficacy as an adjunct to mammography and clinical examination.
The deal is part of CTIs ongoing effort to strengthen its business. In June, the Layton, UT, company consolidated its subsidiary, Thermal Medical Imaging, into its operations, a move it hoped would eliminate confusion about the two companies and their relationship to each other, as well as streamline CTIs management and accounting functions (SCAN 6/9/99).
In other CTI news, the company has received approval from the Food and Drug Administration for the first module of a five-part pre-market approval application (PMA) for its breast cancer detection system. The remaining modules of the application are being prepared and will be submitted as they are completed, according to the company. CTIs PMA covers the use of its device as an adjunct to mammography. The firm is conducting trials with the unit at five hospitals across the U.S.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.
